

Press Release

Boehringer Ingelheim and MorphoSys Enlarge Collaboration

Ingelheim, 18 March 2005 – **Boehringer Ingelheim** and **MorphoSys AG** (Frankfurt: MOR; Prime Standard Segment, TecDAX) announced today an expansion of their existing cooperation involving both research and therapeutic applications. Under the new contract, **Boehringer Ingelheim** has acquired an option to receive several exclusive licenses on new therapeutic antibody programs. The two companies presently have two therapeutic antibody programs in joint collaboration. Additionally, **Boehringer Ingelheim** will obtain access to **MorphoSys'** **HuCAL GOLD[®]** library for research purposes at a number of the firm's research facilities. The first installation site is intended to be **Boehringer Ingelheim's** site in Vienna, Austria. **MorphoSys** will receive a technology access fee, annual license fees and optional R&D funding over the five-year collaboration term. For therapeutic antibodies emerging from the collaboration, **Boehringer Ingelheim** will pay milestone fees and royalties to **MorphoSys**. Financial details of the agreement were not disclosed.

Since February 2003, **Boehringer Ingelheim** and **MorphoSys** have been working jointly on the development of therapeutic antibodies using **MorphoSys'** **HuCAL[®]** technology.

“The extended collaboration with **MorphoSys** will strengthen our capability to generate innovative human monoclonal antibodies and to discover new therapeutic entities,” said Prof Dr Mikael Dolsten, Head of Corporate Research at **Boehringer Ingelheim**. “We are very pleased to continue this collaboration with the aim of providing novel future biological treatment options for patients suffering from cancer, immune, inflammatory and other severe human diseases.”

“We are very pleased about the continued commitment shown by our partner, **Boehringer Ingelheim**, to extensive use of our **HuCAL GOLD[®]** technology,” stated Dr. Simon Moroney, Chief Executive Officer of **MorphoSys AG**. “Alongside the two antibody programs already being actively pursued as part of our partnership, this new agreement significantly

Boehringer Ingelheim GmbH

CD Communications

Binger Straße 173
55216 Ingelheim am Rhein

www.boehringer-ingelheim.com

Phone +49/61 32/77-97296

Fax +49/61 32/77-6601

expands the research applications of our technology, and promises to lead to additional therapeutic projects in the future.”

About Boehringer Ingelheim:

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2003, Boehringer Ingelheim posted net sales of 7.4 billion euro while spending more than one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com

About MorphoSys:

MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL[®]) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Bayer (Berkeley, California/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (New Jersey/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Novartis AG (Basel, Switzerland), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). Additionally, MorphoSys is active in the antibody research market through its Antibodies by Design business unit. Antibodies by Design was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005. For further information please visit the corporate website at: <http://www.morphosys.com/>.

For more information, please contact:

Boehringer Ingelheim

Ute Schmidt

Boehringer Ingelheim

External Communications

Phone: +49 6132 7797296

Fax: +49 6132 776601

MorphoSys AG

Dave Lemus

Chief Financial Officer

Phone: +49 (0) 89 / 899 27-439

Fax: +49 (0) 89 / 899 27-5439

investors@morphosys.com

Dr. Claudia Gutjahr-Löser

Director Corporate Communications

Phone: +49 (0) 89 / 899 27-122

Fax: +49 (0) 89 / 899 27-5122

gutjahr-loeser@morphosys.com

Mario Brkulj

PR Specialist

Phone : +49 (0) 89 / 899 27-454

Fax: +49 (0) 89 / 899 27-5454

brkulj@morphosys.com